UNAIDS/99.31E (English original, June 1999)
1st revision, April 2000
Regional action plan 2019-2023
J Nepal Health Res Counc 2013 May;11(24):198-204
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...pid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more
Report by the Director-General. 75th World health assembly 25 April 2022
The vision of the new Strategic Action Plan for Strengthening HIS in Myanmar 2017- 2021 is “A strong health information system for a strong health system”. The mission statement of HIS in Myanmar also developed during the strategic planning exercise is “Generating and making accessible compreh...ensive, integrated and timely health information for decision making at different levels of health system”. The goal of the HIS in Myanmar formulated during the assessment is “ To provide complete, valid, reliable and timely health information for making right decisions at the right time to ensure an equitable, effective, efficient and responsive health system”.
more
More and more countries are completing their epidemiological mapping of trachoma in suspected
endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of
“trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass... drug
administration (MDA) is normally at the district level and targets the whole population with Zithromax®
tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5
years of age; and tetracycline eye ointment 1% for infants up to 6 months old.
more
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858–864.Namibia ranks among the 30 high TB burden countries worldwide. Here, we report results of the second nationwide anti-TB drug resistance survey. To assess the prevalence and trends of multidrug-resistant TB (MDR-TB) in Namibia.
From 2014 to 2015, pat...ients with presumptive TB in all regions of Namibia had sputum subjected to mycobacterial culture and phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ethambutol and streptomycin if positive on smear microscopy and/or Xpert MTB/RIF.
more
Meeting report, Kampala, Uganda,
7–8 November 2023
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME